Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Wyeth announces partnership with Santaris

Wyeth announces partnership with Santaris

13th January 2009

Wyeth Pharmaceuticals has announced a strategic alliance deal with Santaris.

The collaboration will see the companies discovering, developing and commercialising new products, based on Santaris’ proprietary Locked Necleic Acid drug platform.

As a result of the agreement, Wyeth will pay its partner an upfront fee of $7 million (4.7 million pounds) in cash, while also making a $10 million equity investment in the organisation.

Santaris may additionally receive milestone payments of up to $83 million for reaching each of the ten potential targets.

The drug platform allows for specific targeting and regulation of microRNAs and messenger RNAs, as a way to affect gene expression mediated by the targeted ribonucleic acid molecules.

Mikael Dolsten, president of Wyeth Research, said: “With this alliance, Wyeth explores a fourth platform technology targeting RNAs, which complements our expertise in small molecules, vaccines and protein-based therapeutics.”

He added the partnership will increase the ability to develop and commercialise products that “have a potential to address significant unmet needs in critical therapeutic areas”.

Last month, Wyeth announced it had acquired Thiakis.

The $30 million transaction is also set to see additional payments of up to $120 million.

Thiakis’ product candidate TKS1225 is currently being studied as a potential treatment of medical obesity and other related conditions.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.